News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Bone Drug Shows Benefits So Trial is Stopped


7/12/2012 6:46:50 AM

Merck & Co. (MRK) will stop testing an experimental therapy meant to prevent bone fractures in women with osteoporosis because the drug has worked so well in a late- stage trial. The shares rose in early trading. The drug, odanacatib, has been tested in post-menopausal women with osteoporosis since 2007, Merck said in a statement. An advisory panel monitoring the results recommended closing the phase 3 study early “due to robust efficacy and a favorable benefit-risk profile,” Whitehouse Station, New Jersey-based Merck said yesterday in the statement.

Read at Bloomberg
Read at Reuters
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES